Choriodecidual inflammation: A potentially preventable cause of perinatal HIV-1 transmission?

Lancet

Volumn 352, Issue 9144, 1998, Pages 1927-1930

  Goldenberg, Robert L ^a   Vermund, Sten H ^a   Goepfert, Alice R ^a   Andrews, William W ^a  

^a UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE;

AMNION; AMNION FLUID LEVEL; ANTIBIOTIC THERAPY; ARTICLE; CHORIOAMNIONITIS; CHOROID; DECIDUA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; INFECTION RISK; INFLAMMATION; LEUKOCYTE; NONHUMAN; OBSTETRICS; PERINATAL INFECTION; PREMATURITY; PRIORITY JOURNAL; VERTICAL TRANSMISSION;

EID: 0032512304     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)04453-5     Document Type: Note

References (25)

1. 1 Connor EM, Sperling RS, Gelber R, et al. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group. N Engl J Med 1994; 331: 1173-80.
2. 2 Giaquinto C, Truscia D, De Rossi A, et al. European Collaborative Study. Risk factors for mother-to-child transmission of HIV-1. Lancet 1992; 339: 1007-12.
3. 3 St Louis ME, Kamenga M, Brown C, et al. Risk for perinatal HIV-1 transmission according to maternal immunologic, virologic, and placental factors. JAMA 1993; 269: 2853-59.
4. 4 Popek EJ, Korber BT, Merritt L, et al. Acute chorioamnionitis and duration of membrane rupture correlates with vertical transmission of HIV-1. 4th Conference on Retroviruses and Opportunistic Infections 1997; 158 (abstr no 504).
5. 5 Nyongo A, Gichangi P, Temmerman M, Ndinya-Achola JO. HIV infection as a risk factor for chorioamnionitis in preterm birth. Int Conf AIDS 1992; 8 (2): B165 (abstr no PoB 3469).
6. 6 Minkoff H, Burns DN, Landesman S, et al. The relationship of the duration of ruptured membranes to vertical transmission of human immunodeficiency virus. Am J Obstet Gynecol 1995; 173: 585-89.
7. 7 Mofenson LM. Interacton between timing of perinatal human immunodeficiency virus infection and the design of preventive and therapeutic interventions. Acta Paediatr Suppl 1997; 491: 1-9.
8. 8 Mundy DC, Schinazi RF, Gerber AR, Nahmias AJ, Randall HW Jr. Human immunodeficiency virus isolated from amniotic fluid. Lancet 1987; ii: 549-60.
9. 9 Rasheed S, Li Z, Xu D, Kovacs A. Presence of cell-free human immunodefiency virus in cervicovaginal secretions is independent of viral load in the blood of human immunodeficiency virus-infected women. Am J Obstet Gynecol 1996; 175: 122-29.
10. 10 Andrews WW, Goldenberg RL, Hauth JC. Preterm labor: emerging role of genital tract infections. Infect Agents Dis 1995; 4: 196-211.
11. 11 Melendez-Guerrero L, Holmes R, Backe E, et al. In vitro infection of Hofbauer cells with a monocyte-tropic strain of HIV-1. Trophoblast Res 1994; 8: 33-45.
12. 12 Goldenberg RL, Iams JD, Mercer BM, Meis PJ, Moawad AH, Copper RL. The preterm prediction study: fetal fibronectin, bacterial vaginosis and peripartum infection. Obstet Gynecol 1996; 87: 656-60.
13. 13 Hauth JC, Goldenberg RL, Andrews WW, DuBard MB, Cooper RL. Reduced incidence of preterm delivery with metronidazole and erythromycin in women with bacterial vaginosis. N Engl J Med 1995; 333: 1732-36.
14. 14 Norman K, Pattinson RC, de Souza J, de Jong P, Moller G, Kirsten G. Ampicillin and metronidazole treatment in preterm labour: a multicentre, randomised controlled trial. Br J Obstet Gynecol 1994; 101: 404-08.
15. 15 Goldenberg RL, Andrews WW, Yuan AA, MacKay T, St Louis M. Sexually transmitted diseases and adverse outcomes of pregnancy. Clin Perinatol 1997; 24: 23-41.
16. 16 Fiscella K. Racial disparities in preterm births. The role of urogenital infections. Public Health Rep 1996; 111: 104-13.
17. 17 Taha TE, Kumwenda N, Liomba G, et al. Heterosexual and perinatal transmission of HIV-1: associations with bacterial vaginosis (BV). XIth World AIDS Conference, Geneva, Switzerland, July, 1998: (abstr 527).
18. 18 Biggars RJ, Miotti PG, Taha TE, et al. Perinatal intervention trial in Africa: effect of a birth canal cleansing intervention to prevent HIV transmission. Lancet 1996; 347: 1647-50.
19. 19 Mercer BM, Miodovnik M, Thurnau GR, et al. Antibiotic therapy for the reduction of morbidity and mortality after preterm premature rupture of the membranes. JAMA 1997; 278: 989-95.
20. 20 Mandelbrot L, Le Chenadec J, Berrebi A, et al. Perinatal HIV-1 transmission interaction between zidovudine prophylaxis and mode of delivery in the French perinatal (chart).
21. 21 Schaefer A, Kriese K, Lauper U, et al. Influence of cesarean section before parturition and antiretroviral prophylaxis on the materno-fetal transmission of HIV. XIIth World AIDS Conference, Geneva, Switzerland, July, 1998: (abstr 12466).
22. 22 Schafer AP. Cytokine network during pregnancy and consequences for HIV transmission. Int Conf AIDS 1993; 9: 91.
23. 23 Fazely F, Sharma PL, Fratazzi C, et al. Simian immunodeficency virus infection via amniotic fluid: a model to study fetal immunopathogenesis and prophylaxis. J Acquir Immune Defic Syndr 1993; 6: 107-14.
24. 24 Mortality and Morbidity World Report. Administration of zidovudine during late pregnancy and delivery to prevent perinatal HIV transmission - Thailand, 1996-1998. JAMA 1998; 279: 1061-62.
25. 25 Mansergh G, Haddix AC, Steketee RW, et al. Cost-effectiveness of short-course zidovudine to prevent perinatal HIV type 1 infection in a sub-Saharan African developing country setting. JAMA 1996; 276: 139-45.